One of the most significant events that occurred in the bio-pharmaceutical sector in recent years was the ruling made on the Amgen vs. Sanofi patent dispute in the United States.

In May last year, the U.S. Supreme Court issued its final ruling on the patent dispute between the two biotech giants. The case received special attention, as the dispute over the validity or invalidity of patents lasted for nearly a decade in the KRW 1 trillion drug market and the first in a long time the U.S. Supreme Court ruled on the 'enablement requirement' of a patent.

In 2011, Amgen and Sanofi each patented an antibody for the treatment of hyperlipidemia that binds to the PCSK9 protein, and developed Rep